Unnamed: 0 int64 0 350k | ApplicationNumber int64 9.75M 96.1M | ArtUnit int64 1.6k 3.99k | Abstract stringlengths 7 8.37k | Claims stringlengths 3 292k | abstract-claims stringlengths 68 293k | TechCenter int64 1.6k 3.9k |
|---|---|---|---|---|---|---|
1,100 | 15,281,543 | 1,619 | The present invention relates to new rifaximin forms comprising solid dispersions of rifaximin, methods of making same and to their use in medicinal preparations and therapeutic methods. | 1. A pharmaceutical composition comprising
from about 33 wt % to about 35 wt % rifaximin; from about 33 wt % to about 35 wt % HPMC-AS; from about 3 wt % to about 5 wt % poloxamer 407; from about 4 wt % to about 14 wt % croscarmellose sodium; from about 10 wt % to about 19 wt % microcrystalline cellulose; from about 0.1... | The present invention relates to new rifaximin forms comprising solid dispersions of rifaximin, methods of making same and to their use in medicinal preparations and therapeutic methods.1. A pharmaceutical composition comprising
from about 33 wt % to about 35 wt % rifaximin; from about 33 wt % to about 35 wt % HPMC-AS;... | 1,600 |
1,101 | 14,764,751 | 1,611 | The invention relates to a composition comprising, in a physiologically acceptable aqueous medium, a dicarboxylic acid containing from 2 to 8 carbon atoms, and a plant oil of triglyceride type with a fatty acid fraction comprising not more than 20% by weight of oleic acid, the composition having a pH ranging from 7 to ... | 1-12. (canceled) 13. A composition comprising, in a physiologically acceptable aqueous medium:
a dicarboxylic acid containing from 2 to 8 carbon atoms, and a plant oil of triglyceride type with a fatty acid fraction comprising not more than 20% by weight of oleic acid, wherein the composition has a pH ranging from abou... | The invention relates to a composition comprising, in a physiologically acceptable aqueous medium, a dicarboxylic acid containing from 2 to 8 carbon atoms, and a plant oil of triglyceride type with a fatty acid fraction comprising not more than 20% by weight of oleic acid, the composition having a pH ranging from 7 to ... | 1,600 |
1,102 | 14,410,887 | 1,627 | Disclosed herein are methods and compositions related to the discovery that cholesterol inhibitors induce the anti-proliferative protein, estrogen receptor beta (ERβ), in both ERα-positive and ERα-negative breast cancer cell lines, including triple negative cells. | 1.-49. (canceled) 50. A method of treatment of cancer in a subject, comprising:
i) administering an amount of cholesterol biosynthesis inhibitor sufficient to induce ERβ in cancer cells; and ii) administering a therapeutically effective amount of a selective or nonselective ERβ agonist;
wherein these steps may be perf... | Disclosed herein are methods and compositions related to the discovery that cholesterol inhibitors induce the anti-proliferative protein, estrogen receptor beta (ERβ), in both ERα-positive and ERα-negative breast cancer cell lines, including triple negative cells.1.-49. (canceled) 50. A method of treatment of cancer in... | 1,600 |
1,103 | 16,038,929 | 1,612 | An oral care composition, including a structurant including a carboxypolymethylene polymer, a humectant including glycerin, a whitening agent including hydrogen peroxide, and a carrier including water, wherein the oral care composition has a pH from about 4 to about 6, a transmission rate of at least 58%, a refraction ... | 1. An oral care composition, comprising:
from about 2 weight % to about 6 weight % of a structurant comprising a carboxypolymethylene polymer, based on a total weight of the oral care composition; from about 20 weight % to about 40 weight % of a humectant comprising glycerin, based on the total weight of the oral care ... | An oral care composition, including a structurant including a carboxypolymethylene polymer, a humectant including glycerin, a whitening agent including hydrogen peroxide, and a carrier including water, wherein the oral care composition has a pH from about 4 to about 6, a transmission rate of at least 58%, a refraction ... | 1,600 |
1,104 | 15,444,445 | 1,633 | A method is used for preparing a product for use in repairing a lesion or defect at a tissue site in a human or animal patient body. The method includes obtaining tissue from a donor human or animal body and freezing the obtained tissue. The method further includes pulverizing the frozen tissue and suspending the pulve... | 1. A method for preparing a product for use in repairing a lesion or defect at a tissue site in a human or animal patient body, the method comprising:
obtaining tissue from a donor human or animal body; freezing the obtained tissue; pulverizing the frozen tissue; suspending the pulverized tissue in a fluid; homogenizin... | A method is used for preparing a product for use in repairing a lesion or defect at a tissue site in a human or animal patient body. The method includes obtaining tissue from a donor human or animal body and freezing the obtained tissue. The method further includes pulverizing the frozen tissue and suspending the pulve... | 1,600 |
1,105 | 15,850,416 | 1,616 | A method and corresponding pharmaceutical composition for inhibiting the growth of fungi. The method uses an antifungal composition containing as the active ingredient one or more nylon-3 copolymers having a formula:
... | 1. A method of inhibiting fungal growth, the method comprising:
contacting fungi with a composition comprising a nylon-3 copolymer having a formula:
or a salt thereof,
wherein:
each R is independently hydrogen or C1-C6-alkyl;
each R1, R3, R4, R5, and R6 are each independently selected from the group consist... | A method and corresponding pharmaceutical composition for inhibiting the growth of fungi. The method uses an antifungal composition containing as the active ingredient one or more nylon-3 copolymers having a formula:
... | 1,600 |
1,106 | 16,216,225 | 1,616 | Proppants are used in oil and gas extraction, particularly in fracking operations. The invention relates to resin coated proppants. The coatings on proppants have antimicrobial materials incorporated within these coatings. The antimicrobially active agents are incorporated in a concentration less than 70% by weight of ... | 1. An oil field proppant comprising frac sand or an aluminum oxide-containing particulate wherein said proppant is coated with a polymer coating containing at least one antimicrobial material wherein the weight percent of the antimicrobial material is greater than 20 wt. % and less than 70 wt. % as compared to the weig... | Proppants are used in oil and gas extraction, particularly in fracking operations. The invention relates to resin coated proppants. The coatings on proppants have antimicrobial materials incorporated within these coatings. The antimicrobially active agents are incorporated in a concentration less than 70% by weight of ... | 1,600 |
1,107 | 14,706,165 | 1,633 | The present invention discloses recovery and isolation of mesenchymal stem cells from the peripheral blood. This has an advantage of being able to obtain multilineage inducible cells from readily obtainable and autologous allogenic blood. With the present invention it is no longer necessary to depend on cadaver donor b... | 1. A composition of isolated, post-natal, multilineage inducible, morphologically distinct cells from the peripheral blood which express at least CD90. 2. The composition of claim 1 wherein the cells are isolated from a biological sample of the peripheral blood, human or animal. 3. The composition of claim 1 wherein th... | The present invention discloses recovery and isolation of mesenchymal stem cells from the peripheral blood. This has an advantage of being able to obtain multilineage inducible cells from readily obtainable and autologous allogenic blood. With the present invention it is no longer necessary to depend on cadaver donor b... | 1,600 |
1,108 | 12,058,387 | 1,612 | The invention relates to novel arginine salts, compositions comprising them, and their uses. | 1. A salt of arginine and one or more of the following conjugate acids:
a. an acidic polymer; b. a conjugate acid of an anionic surfactant salt; c. a polyphosphoric or polyphosphonic acid, or d. an acidic antimicrobial agent. 2. The salt of claim 1 in solid form. 3. The salt of claim 1, wherein the conjugate acid is an... | The invention relates to novel arginine salts, compositions comprising them, and their uses.1. A salt of arginine and one or more of the following conjugate acids:
a. an acidic polymer; b. a conjugate acid of an anionic surfactant salt; c. a polyphosphoric or polyphosphonic acid, or d. an acidic antimicrobial agent. 2.... | 1,600 |
1,109 | 15,805,219 | 1,612 | This application provides, among other things, novel aqueous biphasic compositions comprising two distinct aqueous phases, useful for combining and delivering poorly compatible ingredients, for example to deliver effective levels of cationic antibacterial agents in combination with anionic polymers, e.g. that protect a... | 1. A composition comprising an aqueous solution of
a) an acidic polymer; b) a nonionic polymer; c) optionally an effective amount of cationic active agent; d) a stabilizing amount of a polyamine compound; and e) water; wherein the solution comprises two distinct aqueous phases having different composition and density. ... | This application provides, among other things, novel aqueous biphasic compositions comprising two distinct aqueous phases, useful for combining and delivering poorly compatible ingredients, for example to deliver effective levels of cationic antibacterial agents in combination with anionic polymers, e.g. that protect a... | 1,600 |
1,110 | 12,841,331 | 1,618 | A nanodevice has a containment vessel defining a storage chamber therein and defining at least one port to provide access to and from said storage chamber, and a stopper assembly attached to the containment vessel. The stopper assembly has a blocking unit arranged proximate the at least one port and has a structure sui... | 1. A nanodevice, comprising:
a containment vessel defining a storage chamber therein and defining at least one port to provide access to and from said storage chamber; and a stopper assembly attached to said containment vessel, said stopper assembly comprising a blocking unit arranged proximate said at least one port a... | A nanodevice has a containment vessel defining a storage chamber therein and defining at least one port to provide access to and from said storage chamber, and a stopper assembly attached to the containment vessel. The stopper assembly has a blocking unit arranged proximate the at least one port and has a structure sui... | 1,600 |
1,111 | 15,867,985 | 1,612 | The present invention is directed to carrier systems comprising ether-lipids conjugated to one or more bioactive ligands and exposed on the surface of the carrier system for use in targeted delivery and/or antigen display systems. Optionally one or more further bioactive agents may be encapsulated or embedded within or... | 1-18. (canceled) 19. A carrier system comprising a compound of formula I
wherein
Y represents O, N, S or a covalent bond,
S1, S2, S3 represent independently of each other a covalent bond or a spacer group,
X1, X2, X3 represent independently of each other H or a ligand group or any two of X1, X2, X3 may togeth... | The present invention is directed to carrier systems comprising ether-lipids conjugated to one or more bioactive ligands and exposed on the surface of the carrier system for use in targeted delivery and/or antigen display systems. Optionally one or more further bioactive agents may be encapsulated or embedded within or... | 1,600 |
1,112 | 15,771,884 | 1,618 | A seal formulation for forming a physical barrier in the teat canal of a non-human animal for prophylactically controlling infection of a mammary gland by a mastitis-causing organism comprises a polymer in a gel base wherein the polymer is a lower alkyl vinyl ether-maleic anhydride copolymer or a salt derivative thereo... | 1-40. (canceled) 41. A seal formulation for forming a physical barrier in the teat canal of a non-human animal comprising a polymer in a gel base wherein the polymer is a lower alkyl vinyl ether-maleic anhydride copolymer or a salt derivative thereof. 42. A seal formulation as claimed in claim 41 wherein the lower alky... | A seal formulation for forming a physical barrier in the teat canal of a non-human animal for prophylactically controlling infection of a mammary gland by a mastitis-causing organism comprises a polymer in a gel base wherein the polymer is a lower alkyl vinyl ether-maleic anhydride copolymer or a salt derivative thereo... | 1,600 |
1,113 | 16,399,772 | 1,699 | A bodypainting ink includes a coloring agent, a solvent, and a resin. The coloring agent includes an anion coloring agent, the resin includes a cation monomer, and a molar ratio of cations, constituting the cation monomer, to anions, constituting the anion coloring agent, is 1 or more. | 1. A bodypainting ink, including:
a coloring agent; a solvent; and a resin, wherein the coloring agent comprises an anion coloring agent, the resin includes a cation monomer, and a molar ratio of cations, constituting the cation monomer, to anions, constituting the anion coloring agent, is 1 or more, and wherein the so... | A bodypainting ink includes a coloring agent, a solvent, and a resin. The coloring agent includes an anion coloring agent, the resin includes a cation monomer, and a molar ratio of cations, constituting the cation monomer, to anions, constituting the anion coloring agent, is 1 or more.1. A bodypainting ink, including:
... | 1,600 |
1,114 | 15,500,615 | 1,644 | The invention relates to an isolated anti-CD45RC antibody for use in preventing or treating transplant rejection, autoimmune diseases, unwanted immune responses against proteins expressed in the course of gene therapy and/or therapeutic proteins, allergy as well as lymphoma or cancer which are associated with CD45RC + ... | 1. A method of i) preventing or reducing allogeneic transplant rejection or 2) preventing or treating an autoimmune disease, an unwanted immune response against therapeutic protein, an allergy, or a lymphoma or cancer which is associated with CD45RC+ cells in a patient in need thereof, comprising
administering to the p... | The invention relates to an isolated anti-CD45RC antibody for use in preventing or treating transplant rejection, autoimmune diseases, unwanted immune responses against proteins expressed in the course of gene therapy and/or therapeutic proteins, allergy as well as lymphoma or cancer which are associated with CD45RC + ... | 1,600 |
1,115 | 15,022,429 | 1,619 | The present invention discloses a scalable and solvent-free method to produce cocrystals in a particulate form. A method of making cocrystals comprises the steps of: a) feeding a molten mixture of at least a first substance and a second substance which are able to form cocrystals to an atomizer; b) atomizing the molten... | 1. A method of making cocrystals, which method comprises the steps of:
a) feeding a molten mixture of at least a first substance and a second substance which are able to form cocrystals to an atomizer; b) atomizing the molten mixture to droplets; c) solidifying the droplets to particles; d) collecting the said particle... | The present invention discloses a scalable and solvent-free method to produce cocrystals in a particulate form. A method of making cocrystals comprises the steps of: a) feeding a molten mixture of at least a first substance and a second substance which are able to form cocrystals to an atomizer; b) atomizing the molten... | 1,600 |
1,116 | 13,972,539 | 1,619 | Provided are functional segregated telodendrimers having, for example, two or three functional segments. The telodendrimers can have one or more crosslinking groups (e.g., reversible photocrosslinking groups). The telodendrimers can aggregate to form nanocarriers. Cargo such as drugs, imaging probes, and other material... | 1. A compound of formula (I):
wherein
PEG is optionally present and is a polyethylene glycol moiety, wherein PEG has a molecular weight of 44 Da to 100 kDa;
A is a monomer or oligomer;
X is a branched monomer unit;
each L1 is independently optional and is a linker group;
each L2 is independently optional and ... | Provided are functional segregated telodendrimers having, for example, two or three functional segments. The telodendrimers can have one or more crosslinking groups (e.g., reversible photocrosslinking groups). The telodendrimers can aggregate to form nanocarriers. Cargo such as drugs, imaging probes, and other material... | 1,600 |
1,117 | 14,240,903 | 1,646 | The present invention relates to inhibitors of antithrombin III and the medical use thereof in treating or preventing bleeding. The inhibitors are preferably used in subjects suffering from an acquired or genetic bleeding disorder, such as haemophilia, or in a subjects having a clinical condition characterised by exces... | 1-15. (canceled) 16. A method for treating or reducing the risk of bleeding in a subject who has a genetic or acquired bleeding disorder or a clinical condition characterized by excessive bleeding, which method comprises administering to the subject an effective amount of an inhibitor of antithrombin III. 17. The metho... | The present invention relates to inhibitors of antithrombin III and the medical use thereof in treating or preventing bleeding. The inhibitors are preferably used in subjects suffering from an acquired or genetic bleeding disorder, such as haemophilia, or in a subjects having a clinical condition characterised by exces... | 1,600 |
1,118 | 15,131,442 | 1,628 | A composition effective to relax smooth muscles in an individual in an altered state is described. The composition includes a dosage of GABA or GABA-a analogue, and a dosage of at least one of an ACE inhibitor and an ARB combined with the dosage of GABA or GABA-a analogue into a deliverable form. | 1-10. (canceled) 11. A method of relaxing smooth muscles in an individual having GABA receptors expressed in the individual's smooth muscles and endothelium, the method comprising the steps of:
providing a composition of a dosage of GABA or GABA-a analogue and a dosage of at least one of an ACE inhibitor and a ARB comb... | A composition effective to relax smooth muscles in an individual in an altered state is described. The composition includes a dosage of GABA or GABA-a analogue, and a dosage of at least one of an ACE inhibitor and an ARB combined with the dosage of GABA or GABA-a analogue into a deliverable form.1-10. (canceled) 11. A ... | 1,600 |
1,119 | 14,616,565 | 1,634 | The present invention discloses methods, kits, and apparatus as well as reagents and compositions associated therewith for deriving an indicator for use in diagnosing the presence, absence or degree of at least one condition in a biological subject or in prognosing at least one condition in a biological subject. Also d... | 1. A composition comprising at least one pair of reverse transcribed mRNAs and at least one oligonucleotide primer or probe that hybridizes to an individual one of the reverse transcribed mRNAs, the at least one pair of reverse transcribed mRNAs comprising a first pair and a second pair of reverse transcribed mRNAs, wh... | The present invention discloses methods, kits, and apparatus as well as reagents and compositions associated therewith for deriving an indicator for use in diagnosing the presence, absence or degree of at least one condition in a biological subject or in prognosing at least one condition in a biological subject. Also d... | 1,600 |
1,120 | 15,941,753 | 1,654 | Recent reports detail the pleiotropic roles sirtuins play in repressing premature aging, delaying cellular senescence, enhancing longevity, and ameliorating a wide range of aging disorders. Herein, we report our findings on the potent sirtuin activator, decapeptide-12, and compare its performance to the well documented... | 1. A peptide consisting of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, or SEQ. ID NO: 12. 2. The peptide of claim 1 wherein the peptide consists of SEQ ID NO: 9 modified by a modifying group, the modifying group being either a palmitoyl group or an acetyl group at an amino-terminal end, or amidation of a carboxy-termin... | Recent reports detail the pleiotropic roles sirtuins play in repressing premature aging, delaying cellular senescence, enhancing longevity, and ameliorating a wide range of aging disorders. Herein, we report our findings on the potent sirtuin activator, decapeptide-12, and compare its performance to the well documented... | 1,600 |
1,121 | 14,917,790 | 1,648 | A method for measuring influenza A virus by an immunoassay using an anti-influenza A virus monoclonal antibody which is highly reactive with a wide range of subtypes is disclosed. The method for measuring influenza A virus includes measuring influenza A virus by an immunoassay utilizing antigen-antibody reaction betwee... | 1. A method for measuring influenza A virus, said method comprising measuring influenza A virus by an immunoassay utilizing antigen-antibody reaction between a monoclonal antibody which specifically reacts with matrix protein (M1) of influenza A virus, or an antigen-binding fragment thereof, and influenza A virus in a ... | A method for measuring influenza A virus by an immunoassay using an anti-influenza A virus monoclonal antibody which is highly reactive with a wide range of subtypes is disclosed. The method for measuring influenza A virus includes measuring influenza A virus by an immunoassay utilizing antigen-antibody reaction betwee... | 1,600 |
1,122 | 12,441,844 | 1,617 | A formulation having a slightly water soluble ingredient and method for preparing the same are disclosed. The millbase formulation comprises a slightly water soluble ingredient and a dispersant comprising a water soluble or water dispersible, derivative of an alternating copolymer or a salt thereof. The alternating cop... | 1. A method of formulating a chemical formulation comprising:
providing a slightly water soluble ingredient and a dispersant comprising a water soluble derivative of an alternating copolymer or a salt thereof, wherein the alternating copolymer comprises a residue of a first comonomer and a residue of a second comonomer... | A formulation having a slightly water soluble ingredient and method for preparing the same are disclosed. The millbase formulation comprises a slightly water soluble ingredient and a dispersant comprising a water soluble or water dispersible, derivative of an alternating copolymer or a salt thereof. The alternating cop... | 1,600 |
1,123 | 14,426,484 | 1,631 | Methods for diagnosing the status of periodontitis disease includes selecting a set of protein biomarkers including one or more biomarkers which have been shown to vary in abundance at particular stages of periodontitis. The set of protein biomarkers may be identified and quantified in expression in an acquired gingiva... | 1. A method for diagnosing the status of periodontitis disease, comprising:
providing a gingival crevicular fluid (GCF) sample and a saliva sample; generating a first protein profile by analyzing the proteome of the GCF sample; generating a second protein profile by analyzing the proteome of the saliva sample; determin... | Methods for diagnosing the status of periodontitis disease includes selecting a set of protein biomarkers including one or more biomarkers which have been shown to vary in abundance at particular stages of periodontitis. The set of protein biomarkers may be identified and quantified in expression in an acquired gingiva... | 1,600 |
1,124 | 15,546,476 | 1,627 | Provided is an enema for rectal application containing budesonide as an active ingredient in order to treat inflammatory bowel disease, or to prevent a relapse. The enema for rectal application containing budesonide as the active ingredient, in which 1.5 to 2.5 mg of budesonide per dose is administered twice a day for ... | 1. An enema for rectal application comprising budesonide as an active ingredient, wherein 1.5 to 2.5 mg of budesonide per dose is administered twice a day for 6 weeks in order to treat inflammatory bowel disease, or to prevent a relapse. 2. The enema for rectal application according to claim 1, wherein the dose of bude... | Provided is an enema for rectal application containing budesonide as an active ingredient in order to treat inflammatory bowel disease, or to prevent a relapse. The enema for rectal application containing budesonide as the active ingredient, in which 1.5 to 2.5 mg of budesonide per dose is administered twice a day for ... | 1,600 |
1,125 | 15,292,095 | 1,631 | Methods and compositions for preparation and use of recombinant viruses or other recombinant expression systems are presented in which neoepitopes are first identified in a patient- and cancer-specific manner and then further filtered by HLA-match to the patient. Selected neoepitopes are then expression using sequence ... | 1. A method of treating a cancer in a patient using immunotherapy, comprising:
generating a recombinant nucleic acid configured to express a cancer- and patient-specific neoepitope; wherein the neoepitope is a high-affinity binder to at least one MHC Class I sub-type or at least one MHC Class II sub-type of an HLA-type... | Methods and compositions for preparation and use of recombinant viruses or other recombinant expression systems are presented in which neoepitopes are first identified in a patient- and cancer-specific manner and then further filtered by HLA-match to the patient. Selected neoepitopes are then expression using sequence ... | 1,600 |
1,126 | 14,441,569 | 1,637 | The present invention relates to methods and kits which can be used to amplify nucleic acids with the advantage of decreasing user time and possible contamination. For easy processing and amplification of nucleic acid samples, the samples are bound to a solid support and used directly, without purification, in a nuclei... | 1. A method for amplification of nucleic acid comprising the steps:
i) contacting a solid support comprising a chaotropic salt with a cellular sample containing nucleic acid, ii) transferring said solid support to a reaction vessel, iii) incubating said nucleic acid on the solid support with a nucleic acid amplificatio... | The present invention relates to methods and kits which can be used to amplify nucleic acids with the advantage of decreasing user time and possible contamination. For easy processing and amplification of nucleic acid samples, the samples are bound to a solid support and used directly, without purification, in a nuclei... | 1,600 |
1,127 | 15,329,148 | 1,631 | Provided in the present disclosure are a method and a device for determining a fraction of cell free nucleic acids in a biological sample and use thereof, wherein the method comprises: (1) sequencing nucleic acids of a biological sample having free nucleic acids, in order to obtain sequencing results for a plurality of... | 1. A method for determining a fraction of cell-free nucleic acids from a predetermined source in a biological sample, comprising:
performing sequencing on cell-free nucleic acids contained in the biological sample, so as to obtain a sequencing result consisting of a plurality of sequencing data; determining the number ... | Provided in the present disclosure are a method and a device for determining a fraction of cell free nucleic acids in a biological sample and use thereof, wherein the method comprises: (1) sequencing nucleic acids of a biological sample having free nucleic acids, in order to obtain sequencing results for a plurality of... | 1,600 |
1,128 | 15,471,730 | 1,639 | An array including a solid support having a plurality of contours along its exterior surface. A first subset of contours is positioned along the exterior surface of the solid support to form a first pattern of features and a second subset of contours is positioned along the exterior surface to form a second pattern of ... | 1. An array, comprising:
a solid support comprising a plurality of contours along an exterior surface of the solid support; wherein a first subset of the contours is positioned along the exterior surface of the solid support to form a first pattern of features and a second subset of the contours is positioned along the... | An array including a solid support having a plurality of contours along its exterior surface. A first subset of contours is positioned along the exterior surface of the solid support to form a first pattern of features and a second subset of contours is positioned along the exterior surface to form a second pattern of ... | 1,600 |
1,129 | 14,930,840 | 1,631 | Embodiments are directed to a computer-based system for analyzing genotype data of a set of multiple progeny to estimate information about unknown parents of the multiple progeny. The system includes a memory and a processor system communicatively coupled to the memory. The processor system is configured to receive dat... | 1. A computer-based system for analyzing genotype data of a set of multiple progeny to estimate information about unknown parents of the multiple progeny, the system comprising:
a memory; and a processor system communicatively coupled to the memory; the processor system configured to: receive data representing markers ... | Embodiments are directed to a computer-based system for analyzing genotype data of a set of multiple progeny to estimate information about unknown parents of the multiple progeny. The system includes a memory and a processor system communicatively coupled to the memory. The processor system is configured to receive dat... | 1,600 |
1,130 | 15,835,270 | 1,653 | The present disclosure relates to gastrointestinal (GI) tract detection methods, devices and systems. | 1. A method, comprising:
transferring a fluid sample from the gastrointestinal (GI) tract or from the reproductive tract of a subject into a first dilution chamber of a device in vivo; and combining the fluid sample and a first dilution fluid in the first dilution chamber to produce a first diluted sample. 2-165. (canc... | The present disclosure relates to gastrointestinal (GI) tract detection methods, devices and systems.1. A method, comprising:
transferring a fluid sample from the gastrointestinal (GI) tract or from the reproductive tract of a subject into a first dilution chamber of a device in vivo; and combining the fluid sample and... | 1,600 |
1,131 | 15,327,671 | 1,616 | The application relates to compositions for enhancing plant growth, comprising at least one lipo-chitooligosaccharide (LCO) compound; and one beneficial microorganism selected from Streptomyces, Trichoderma or Bacillus and optionally further pesticide and to the methods for enhancing plant growth and treating seeds... | 1. A method for synergistically enhancing the growth of a plant or plant part, comprising contacting said plant or plant part with at least one lipo-chitooligosaccharide (LCO) and at least one agriculturally beneficial microorganism, said at least one agriculturally beneficial microorganism comprising Bacillus sp., iso... | The application relates to compositions for enhancing plant growth, comprising at least one lipo-chitooligosaccharide (LCO) compound; and one beneficial microorganism selected from Streptomyces, Trichoderma or Bacillus and optionally further pesticide and to the methods for enhancing plant growth and treating seeds... | 1,600 |
1,132 | 16,096,493 | 1,626 | In a process for the synthesis of a nitrile by endothermic catalyzed reaction of ammonia with a hydrocarbon using heating obtained by passing an alternating current through a metallic coil, the endothermic reaction between ammonia and the hydrocarbon takes place in a reactor with direct inductive heating in the reactio... | 1. A process for the synthesis of a nitrile by catalyzed reaction of ammonia with a hydrocarbon using heating obtained by passing an alternating current through a metallic coil, wherein the endothermic reaction between ammonia and the hydrocarbon takes place in a reactor with direct inductive heating in the reaction zo... | In a process for the synthesis of a nitrile by endothermic catalyzed reaction of ammonia with a hydrocarbon using heating obtained by passing an alternating current through a metallic coil, the endothermic reaction between ammonia and the hydrocarbon takes place in a reactor with direct inductive heating in the reactio... | 1,600 |
1,133 | 15,609,564 | 1,612 | The present invention relates to compositions and methods for mineralizing a dental surface or subsurface including providing a composition including stabilized ACP and a source of fluoride ions. | 1-12. (canceled) 13. A method of mineralizing a dental surface or subsurface comprising providing a composition to contact the dental surface or subsurface, wherein the composition, prior to contacting the dental surface or subsurface, comprises (i) about 0.01% to 50% by weight casein phosphopeptide-stabilized amorphou... | The present invention relates to compositions and methods for mineralizing a dental surface or subsurface including providing a composition including stabilized ACP and a source of fluoride ions.1-12. (canceled) 13. A method of mineralizing a dental surface or subsurface comprising providing a composition to contact th... | 1,600 |
1,134 | 14,124,429 | 1,619 | The invention relates to the use of, and methods of use employing, certain glycolipid compounds as defined in detail below and having preservative or antimicrobial properties, novel compounds of the glycolipid class, and related invention embodiments.
The compounds have the formula I
... | 1. Method of preservating a material or imparting antimicrobial properties to said material, said method comprising adding to said material an effective amount therefor of a compound of the formula I, or a mixture of two or more such compounds of the formula I,
wherein m is 3 to 5, n is 2 to 5, o is 0 or 1 a... | The invention relates to the use of, and methods of use employing, certain glycolipid compounds as defined in detail below and having preservative or antimicrobial properties, novel compounds of the glycolipid class, and related invention embodiments.
The compounds have the formula I
... | 1,600 |
1,135 | 15,306,163 | 1,633 | Disclosed are AAV viral-based vector compositions useful in delivering a variety of nucleic acid segments, including those encoding therapeutic polypeptides to selected mammalian host cells for use in therapeutic autoimmune modalities, including, for example, the in vivo induction of immunological tolerance via a liver... | 1. A recombinant adeno-associated viral (rAAV) nucleic acid vector comprising:
a polynucleotide that includes a nucleic acid segment that encodes a first autoimmune disease therapeutic molecule operably linked to a promoter that is capable of expressing the nucleic acid segment in one or more cells of a mammalian liver... | Disclosed are AAV viral-based vector compositions useful in delivering a variety of nucleic acid segments, including those encoding therapeutic polypeptides to selected mammalian host cells for use in therapeutic autoimmune modalities, including, for example, the in vivo induction of immunological tolerance via a liver... | 1,600 |
1,136 | 16,322,571 | 1,627 | The present invention relates to a pharmaceutical composition comprising pomalidomide, maltodextrin and a filler, wherein the weight ratio of maltodextrin to filler ranges from 1:1 to 1:2. The invention further relates to the use of said pharmaceutical composition as medicament in the treatment of multiple myeloma. | 1. A pharmaceutical composition comprising pomalidomide, maltodextrin and a filler, wherein the weight ratio of maltodextrin to filler ranges from 1:1 to 1:2. 2. The composition according to claim 1, wherein the maltodextrin has a dextrose equivalent (DE) of 11 to 14. 3. The composition according to claim 1, wherein th... | The present invention relates to a pharmaceutical composition comprising pomalidomide, maltodextrin and a filler, wherein the weight ratio of maltodextrin to filler ranges from 1:1 to 1:2. The invention further relates to the use of said pharmaceutical composition as medicament in the treatment of multiple myeloma.1. A... | 1,600 |
1,137 | 15,758,828 | 1,616 | The present disclosure provides stable inoculant compositions and methods for enhancing the survival and/or stability of microorganisms in an inoculant composition. In some embodiments, the microorganisms in an inoculant compositions are stabilized by the presence of one or more maltodextrins having a dextrose equivale... | 1. An aqueous inoculant composition comprising:
one or more maltodextrins having a dextrose equivalent value of about 15 to about 20; maltose; and one or more strains of Gram-negative bacteria, said one or more maltodextrins and said maltose comprising about 35 to about 65% of said inoculant composition (w/w, based upo... | The present disclosure provides stable inoculant compositions and methods for enhancing the survival and/or stability of microorganisms in an inoculant composition. In some embodiments, the microorganisms in an inoculant compositions are stabilized by the presence of one or more maltodextrins having a dextrose equivale... | 1,600 |
1,138 | 13,391,590 | 1,619 | A composition comprising a pigment particle that is coated with Polyquaternium-67. The pigment particle can be included in a cleansing composition for deposition on a surface, such as skin. | 1. A composition comprising a pigment particle that is coated with Polyquaternium-67. 2. The composition of claim 1, wherein the particle is at least one material chosen from mica/titanium dioxide, mica/iron oxide, mica, titanium dioxide, zinc oxides, iron oxides, chromium oxides, silica, talc, and kaolin. 3. The compo... | A composition comprising a pigment particle that is coated with Polyquaternium-67. The pigment particle can be included in a cleansing composition for deposition on a surface, such as skin.1. A composition comprising a pigment particle that is coated with Polyquaternium-67. 2. The composition of claim 1, wherein the pa... | 1,600 |
1,139 | 16,284,800 | 1,616 | The present invention relates to the use of LCOs in initiating earlier flowering, increased number of buds and flower buds and earlier fruit development in non legume and legume plants, as compared to flowering and fruit development under conditions without use of LCOs, and the enhancement of plant growth and yield ass... | 1. A composition comprising a lipo-chitooligosaccharide (LCO) in an amount effective to initiate early flowering of a non-leguminous plant when said composition is foliarly applied to said non-leguminous plant prior to flowering of said non-leguminous plant. 2. The composition of claim 1, wherein said LCO is present in... | The present invention relates to the use of LCOs in initiating earlier flowering, increased number of buds and flower buds and earlier fruit development in non legume and legume plants, as compared to flowering and fruit development under conditions without use of LCOs, and the enhancement of plant growth and yield ass... | 1,600 |
1,140 | 13,805,578 | 1,637 | Gene-based diagnostics capable of rapidly discriminating selected strains of a selected pathogen from other populations within the same species are disclosed. Sequence-specific, real-time monitoring of LAMP of DNA may be accomplished through the use of oglionucleotide probes, referred to as “assimilating probes.” The a... | 1. A method of monitoring LOOP-mediated isothermal amplification (LAMP) of a target DNA, comprising:
contacting an assimilating probe and a DNA polymerase with a LAMP reaction mixture, wherein the LAMP reaction mixture comprises the target DNA and one or more LAMP primers that hybridize with the target DNA, wherein the... | Gene-based diagnostics capable of rapidly discriminating selected strains of a selected pathogen from other populations within the same species are disclosed. Sequence-specific, real-time monitoring of LAMP of DNA may be accomplished through the use of oglionucleotide probes, referred to as “assimilating probes.” The a... | 1,600 |
1,141 | 15,833,127 | 1,617 | The present disclosure provides lubricant compositions suitable for use on human tissue and effective to provide multiple sensations sequentially and/or in varying intensities. The lubricants can include a lubricating base and at least two different sensorial agents effective to impart different sensations, such as war... | 1. A lubricant comprising:
a lubricating base; a first sensorial agent effective to impart a first sensation to contacted human tissue; and a second sensorial agent effective to impart a second sensation to the contacted human tissue, the second sensation being different from the first sensation; wherein onset of the f... | The present disclosure provides lubricant compositions suitable for use on human tissue and effective to provide multiple sensations sequentially and/or in varying intensities. The lubricants can include a lubricating base and at least two different sensorial agents effective to impart different sensations, such as war... | 1,600 |
1,142 | 14,888,259 | 1,615 | The invention relates to an antiseptic material, in particular as a wound dressing, containing a carrier material and at least one antiseptic together with a surfactant, wherein the carrier material is equipped with a cyclodextrin or cyclodextrin derivative that is loaded in the antiseptic or antiseptics. | 1. Antiseptic material, especially wound dressing, containing a carrier material and at least one antiseptic together with a surfactant, wherein the carrier material is finished with a cyclodextrin or cyclodextrin derivative, which is loaded with the antiseptic. 2. Antiseptic material according to claim 1, wherein the ... | The invention relates to an antiseptic material, in particular as a wound dressing, containing a carrier material and at least one antiseptic together with a surfactant, wherein the carrier material is equipped with a cyclodextrin or cyclodextrin derivative that is loaded in the antiseptic or antiseptics.1. Antiseptic ... | 1,600 |
1,143 | 16,859,490 | 1,645 | Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided. | 1.-36. (canceled) 37. A composition comprising:
a replication defective adenovirus vector comprising:
(a) a deletion in the E2b region; and
(b) a nucleic acid sequence encoding an antigen, wherein the antigen is a viral protein, and wherein the virus is a single stranded RNA virus. 38. The composition of claim 37, wher... | Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.1.-36. (canceled) 37. A composition comprising:
a replication defective adenovirus vector comprising:
(a)... | 1,600 |
1,144 | 15,265,709 | 1,645 | Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided. | 1-36. (canceled) 37. A composition comprising a replication defective adenovirus vector comprising:
a deletion in the E2b region; and a nucleic acid sequence encoding Her2/neu. 38. The composition of claim 37, further comprising a replication defective adenovirus vector comprising a nucleic acid sequence encoding a tum... | Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.1-36. (canceled) 37. A composition comprising a replication defective adenovirus vector comprising:
a del... | 1,600 |
1,145 | 15,265,723 | 1,645 | Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided. | 1-36. (canceled) 37. A composition comprising a replication defective adenovirus vector comprising:
a deletion in the E2b region; and a nucleic acid sequence encoding HPV E6, HPV E7 or a combination thereof. 38. The composition of claim 37, further comprising a replication defective adenovirus vector comprising a nucle... | Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.1-36. (canceled) 37. A composition comprising a replication defective adenovirus vector comprising:
a del... | 1,600 |
1,146 | 15,568,487 | 1,631 | Contemplated compositions and methods are directed to cancer neoepitopes and uses of such neoepitopes, especially to generate synthetic antibodies against neoepitopes that may then be employed in the manufacture of a therapeutic agent. Preferred therapeutic agents will comprise a synthetic antibody against a neoepitope... | 1. A method of generating a pharmaceutical agent for cancer immune therapy, comprising:
using matched normal omics data of a tumor to generate in silico a plurality of n-mers that contain at least one patient- and cancer-specific cancer neoepitope; filtering in silico the n-mers to so obtain a subset of neoepitope sequ... | Contemplated compositions and methods are directed to cancer neoepitopes and uses of such neoepitopes, especially to generate synthetic antibodies against neoepitopes that may then be employed in the manufacture of a therapeutic agent. Preferred therapeutic agents will comprise a synthetic antibody against a neoepitope... | 1,600 |
1,147 | 15,744,593 | 1,653 | The invention is in the field of cultures of microalgae, in particular thraustochytrids. The invention relates to a protein-rich biomass of thraustochytrids, to a method of obtaining said biomass, and to the uses thereof. | 1. A thraustochytrid biomass comprising at least 35% by weight of proteins relative to the weight of dry matter. 2. The biomass according to claim 1, wherein it comprises at least 45% proteins. 3. The biomass according to claim 1, wherein it comprises at least 60% proteins. 4. The biomass according to claim 1, wherein ... | The invention is in the field of cultures of microalgae, in particular thraustochytrids. The invention relates to a protein-rich biomass of thraustochytrids, to a method of obtaining said biomass, and to the uses thereof.1. A thraustochytrid biomass comprising at least 35% by weight of proteins relative to the weight o... | 1,600 |
1,148 | 15,306,585 | 1,699 | Cosmetic products, comprising a container having a tubular body, the wall of which has a transmission for visible light of from 25 to about 100%, and on the top end of which a dispenser head is attached, the dispenser head being bounded below by a movable trailing piston, and a cosmetic preparation in the interior of t... | 1.-9. (canceled) 10. A cosmetic product, wherein the product comprises a container and a cosmetic preparation inside the container, the container comprising a tubular body whose walls have a transmittance for visible light of from 25% to about 100% and on whose top end a dispenser head is mounted and which is bounded a... | Cosmetic products, comprising a container having a tubular body, the wall of which has a transmission for visible light of from 25 to about 100%, and on the top end of which a dispenser head is attached, the dispenser head being bounded below by a movable trailing piston, and a cosmetic preparation in the interior of t... | 1,600 |
1,149 | 15,538,326 | 1,627 | The present invention relates to the use of the anti-megakaryocytic agent anagrelide, or a therapeutically active metabolite thereof, in the prevention or treatment of metastatic disease in cancer patients displaying paraneoplastic thrombocytosis. | 1. A compound, wherein the compound is anagrelide, a pharmaceutically acceptable salt, solvate or active metabolite thereof, for use in treating or preventing metastatic disease in a thrombocytotic cancer patient. 2. A compound, wherein the compound is anagrelide, a pharmaceutically acceptable salt, solvate or active m... | The present invention relates to the use of the anti-megakaryocytic agent anagrelide, or a therapeutically active metabolite thereof, in the prevention or treatment of metastatic disease in cancer patients displaying paraneoplastic thrombocytosis.1. A compound, wherein the compound is anagrelide, a pharmaceutically acc... | 1,600 |
1,150 | 16,859,826 | 1,631 | Contemplated panomic systems and methods significantly improve accuracy of genetic testing by taking into account matched normal data and expression levels of various genes in diseased tissue. Analysis and physician guidance is further improved by combining so identified clinically relevant changes with pathway analysi... | 1-14. (canceled) 15. A high throughput computer-based genomic analysis system for reducing false positives and negatives, comprising:
at least one multi-lane sequencing device configured to sequence at least one patient's normal tissue and diseased tissue in a common run;
wherein the at least one sequencing device is f... | Contemplated panomic systems and methods significantly improve accuracy of genetic testing by taking into account matched normal data and expression levels of various genes in diseased tissue. Analysis and physician guidance is further improved by combining so identified clinically relevant changes with pathway analysi... | 1,600 |
1,151 | 15,585,697 | 1,653 | Methods of treating osteoarthritis using protocatechuic acid (PCA) injected into an osteoarthritis joint are provided. | 1. A method of inhibiting interleukin-1 (IL-1) induced glycosaminoglycoside (GAG) release in an arthritic joint of a subject, comprising administering into the arthritic joint of the subject by an intra-articular injection, a composition that is a solution consisting of protocatechuic acid (“PCA”), glucose and a pharma... | Methods of treating osteoarthritis using protocatechuic acid (PCA) injected into an osteoarthritis joint are provided.1. A method of inhibiting interleukin-1 (IL-1) induced glycosaminoglycoside (GAG) release in an arthritic joint of a subject, comprising administering into the arthritic joint of the subject by an intra... | 1,600 |
1,152 | 15,302,796 | 1,619 | Disclosed are cosmetic or pharmaceutical composition comprising a UV filter combination of
(a) an aqueous dispersion of 5,6,5′,6′-tetraphenyl-3,3′-(1,4-Phenylene)bis(1,2,4-Triazine) corresponding to the formula
... | 1.-22. (canceled) 23. A cosmetic or pharmaceutical composition comprising a UV filter combination of
(a) an aqueous dispersion of 5,6,5′,6′-tetraphenyl-3,3′-(1,4-Phenylene)bis(1,2,4-Triazine) corresponding to the formula
in particulate form; and
(b) the UV filters selected from the group consisting of
(b1)... | Disclosed are cosmetic or pharmaceutical composition comprising a UV filter combination of
(a) an aqueous dispersion of 5,6,5′,6′-tetraphenyl-3,3′-(1,4-Phenylene)bis(1,2,4-Triazine) corresponding to the formula
... | 1,600 |
1,153 | 13,709,897 | 1,633 | The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, auto-i... | 1-37. (canceled) 38. A method of treating a cancer disease, cardiovascular disease, infectious disease or autoimmune disease, the method comprising administering a pharmaceutical composition, the pharmaceutical composition comprising a RNA for intracellular expression of an antibody, wherein the RNA contains at least o... | The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, auto-i... | 1,600 |
1,154 | 16,157,225 | 1,628 | The present invention concerns methods for treating and preventing endothelial dysfunction and related disorders, including, for example, pulmonary arterial hypertension, using bardoxolone methyl or analogs thereof. | 1. A method of treating or preventing endothelial dysfunction in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of a compound of the formula:
or a pharmaceutically acceptable salt or tautomer thereof,
wherein the patient has been identified as not havin... | The present invention concerns methods for treating and preventing endothelial dysfunction and related disorders, including, for example, pulmonary arterial hypertension, using bardoxolone methyl or analogs thereof.1. A method of treating or preventing endothelial dysfunction in a patient in need thereof, comprising ad... | 1,600 |
1,155 | 15,765,756 | 1,628 | The present invention relates to methods and pharmaceutical compositions for the treatment of choroidal neovascularisation. In particular, the present invention relates to a method of treating choroidal neovascularisation in a subject in need thereof comprising administering to the subject a therapeutically effective a... | 1. A method of treating choroidal neovascularisation in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a mineralocorticoid receptor antagonist. 2. The method of claim 1 wherein the subject suffers from a disease selected from the group consisting of age-related m... | The present invention relates to methods and pharmaceutical compositions for the treatment of choroidal neovascularisation. In particular, the present invention relates to a method of treating choroidal neovascularisation in a subject in need thereof comprising administering to the subject a therapeutically effective a... | 1,600 |
1,156 | 16,045,338 | 1,613 | A composition for transdermal delivery of a progestin for progestin hormone therapy is disclosed. Also disclosed is a transdermal delivery device comprising the composition. For progestin-only hormone therapy, the composition contains an anti-oxidant and does not contain an estrogen. For therapy involving a progestin a... | 1. An adhesive polymer matrix composition for transdermal delivery of levonorgestrel, wherein:
(a) the composition comprises the levonorgestrel, an anti-oxidant, and a skin permeation enhancer in a polyacrylate pressure sensitive adhesive (PSA); (b) the composition comprises at least one component that contributes to o... | A composition for transdermal delivery of a progestin for progestin hormone therapy is disclosed. Also disclosed is a transdermal delivery device comprising the composition. For progestin-only hormone therapy, the composition contains an anti-oxidant and does not contain an estrogen. For therapy involving a progestin a... | 1,600 |
1,157 | 15,542,500 | 1,615 | This invention relates to the use of the combination of 25-hydroxyvitamin D3 (“25-OH D3”) and antioxidants/anti-inflammatories (ascorbic acid vitamin E and canthaxanthin) to make a premix or feed which can ameliorate various problems observed in companion animals which have been subject to overfeeding. Foods containing... | 1. A food suitable for a companion animal comprising the combination comprising 25-Hydroxy vitamin D (25-OH D), Vitamin C, Vitamin E and a carotenoid selected from the group consisting of: lycopene, astaxanthin, cryptoxanthin, beta-carotene, lutein, zeaxanthin and canthaxanthin. 2. A food according to claim 1 comprisin... | This invention relates to the use of the combination of 25-hydroxyvitamin D3 (“25-OH D3”) and antioxidants/anti-inflammatories (ascorbic acid vitamin E and canthaxanthin) to make a premix or feed which can ameliorate various problems observed in companion animals which have been subject to overfeeding. Foods containing... | 1,600 |
1,158 | 15,542,091 | 1,615 | This invention relates to the use of the combination of 25-hydroxyvitamin D3 (“25-OH D3”) and antioxidants/anti-inflammatories (ascorbic acid vitamin E and canthaxanthin) to make a premix or feed which can ameliorate various problems observed in poultry which have been subject to overfeeding. Feeds containing the 25-OH... | 1. A combination comprising 25-Hydroxy vitamin D, ascorbic acid, Vitamin E and canthaxanthin for use in a poultry feed promoting ovarian health, wherein ovarian health is indicated by at least one indicia of ovarian health selected from the group consisting of:
a) reduced ovarian degeneration, occurrence of ovarian deg... | This invention relates to the use of the combination of 25-hydroxyvitamin D3 (“25-OH D3”) and antioxidants/anti-inflammatories (ascorbic acid vitamin E and canthaxanthin) to make a premix or feed which can ameliorate various problems observed in poultry which have been subject to overfeeding. Feeds containing the 25-OH... | 1,600 |
1,159 | 14,783,699 | 1,648 | The present disclosure provides immunogenic compositions comprising HCV E1, E2, or E1/E2 polypeptides from two or more different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1/E2 polypeptides from two or more different HCV genotypes. The immunogenic compositions are usef... | 1. An immunogenic composition comprising:
a) an hepatitis C virus (HCV) E1 polypeptide, E2 polypeptide or E1E2 polypeptide from a first HCV genotype; b) an HCV E1 polypeptide, E2 polypeptide, or E1E2 polypeptide from a second HCV genotype; and c) a pharmaceutically acceptable excipient, with the proviso that the compos... | The present disclosure provides immunogenic compositions comprising HCV E1, E2, or E1/E2 polypeptides from two or more different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1/E2 polypeptides from two or more different HCV genotypes. The immunogenic compositions are usef... | 1,600 |
1,160 | 14,409,522 | 1,623 | The invention relates to a process for the manufacture of an alkylfluoroacrylate starting from alkylfluoroacetate and an oxalic acid ester, wherein an alkane liquid under the reaction conditions is applied as the solvent in one of the reaction steps. | 1. Process for the manufacture of an alkylfluoroacrylate, comprising the following steps:
A. an alkylfluoroacetate with an ester of oxalic acid is reacted in the presence of a base and a suitable solvent in a crossed Claisen condensation reaction resulting in a Claisen salt, B. the Claisen salt obtained in step A is op... | The invention relates to a process for the manufacture of an alkylfluoroacrylate starting from alkylfluoroacetate and an oxalic acid ester, wherein an alkane liquid under the reaction conditions is applied as the solvent in one of the reaction steps.1. Process for the manufacture of an alkylfluoroacrylate, comprising t... | 1,600 |
1,161 | 12,522,214 | 1,633 | The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, auto-i... | 1. RNA for intracellular expression of an antibody, wherein the RNA contains at least one coding region, wherein at least one coding region codes for at least one antibody. 2. RNA according to claim 1, wherein the RNA is single-stranded or double-stranded, linear or circular, in the form of rRNA, tRNA or mRNA. 3. RNA a... | The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, auto-i... | 1,600 |
1,162 | 14,303,492 | 1,649 | Methods of improving a condition in a subject are provided herein. Aspects of the methods include at least partially restoring normal function of a central nervous system endocrine gland in a manner sufficient to improve the condition in the subject. In some instances, the condition is an aging associated condition. As... | 1. A method of improving a condition in a subject, the method comprising:
at least partially restoring normal function of a central nervous system endocrine gland in a manner sufficient to improve the condition in the subject. 2. The method according to claim 1, wherein the at least partially restoring normal function ... | Methods of improving a condition in a subject are provided herein. Aspects of the methods include at least partially restoring normal function of a central nervous system endocrine gland in a manner sufficient to improve the condition in the subject. In some instances, the condition is an aging associated condition. As... | 1,600 |
1,163 | 15,015,657 | 1,633 | The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoim... | 1. A method of treating a subject comprising administering an effective amount of a pharmaceutical composition comprising mRNA encoding CD20-binding antibody. 2. The method of claim 1, wherein the subject has a cancer. 3. The method of claim 2, wherein the subject has a leukemia, lymphoma or myeloma. 4. The method of c... | The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoim... | 1,600 |
1,164 | 14,871,327 | 1,639 | Disclosed are methods for cell transfection and regulating cellular behavior. More particularly, the present disclosure relates to methods of non-viral cell transfection and regulating cellular behavior using mineral coatings that allow for the enhanced transfection of cells with reduced cytotoxicity. The mineral coati... | 1. A method of non-viral transfection comprising:
preparing a microparticle comprising a mineral coating, wherein the mineral coating is formed by incubating the substrate in a simulated body fluid, wherein the simulated body fluid comprises from about 5 mM to about 12.5 mM calcium ions, from about 2 mM to about 12.5 m... | Disclosed are methods for cell transfection and regulating cellular behavior. More particularly, the present disclosure relates to methods of non-viral cell transfection and regulating cellular behavior using mineral coatings that allow for the enhanced transfection of cells with reduced cytotoxicity. The mineral coati... | 1,600 |
1,165 | 14,128,681 | 1,647 | This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive... | 1. Protein or polypeptide for use in therapy that has a half-life (expressed as t½-beta) in a human subject of at least 3 days, which protein or polypeptide contains an immunoglobulin single variable domain (ISV) at its C-terminal end, wherein said ISV is either a Nanobody or an ISV that comprises a VH sequence (i.e. o... | This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive... | 1,600 |
1,166 | 15,870,745 | 1,619 | The present invention relates to novel anesthetic compositions containing a non-polymeric carrier material and an anesthetic, where the compositions are suitable for providing a sustained local anesthesia without an initial burst and having a duration for about 24 hours or longer. Certain compositions are also provided... | 1. A composition comprising an anesthetic and a pharmaceutically acceptable non-polymeric carrier, wherein the non-polymeric carrier controls release of the anesthetic to provide an anesthetic effect characterized by sustained local anesthesia after administration to a subject without an initial burst and having a dura... | The present invention relates to novel anesthetic compositions containing a non-polymeric carrier material and an anesthetic, where the compositions are suitable for providing a sustained local anesthesia without an initial burst and having a duration for about 24 hours or longer. Certain compositions are also provided... | 1,600 |
1,167 | 16,281,026 | 1,619 | The present invention relates to novel anesthetic compositions containing a non-polymeric carrier material and an anesthetic, where the compositions are suitable for providing a sustained local anesthesia without an initial burst and having a duration for about 24 hours or longer. Certain compositions are also provided... | 1.-181. (canceled) 182. A method for providing an anesthetic effect at a wound in a subject, comprising administering a controlled delivery composition into the wound, wherein the controlled delivery composition comprises bupivacaine, and further wherein the administering provides a sustained local anesthetic effect at... | The present invention relates to novel anesthetic compositions containing a non-polymeric carrier material and an anesthetic, where the compositions are suitable for providing a sustained local anesthesia without an initial burst and having a duration for about 24 hours or longer. Certain compositions are also provided... | 1,600 |
1,168 | 15,323,772 | 1,662 | Compositions and methods are provided for agronomic trait modification of a target sequence in the genome of a plant or plant cell. The methods and compositions employ a guide RNA/Cas endonuclease system to provide an effective system for modifying or altering target sites within a genomic region of a plant, plant cell... | 1. A method of improving an agronomic trait of a plant, the method comprising providing a guide RNA that targets a polynucleotide involved in improving one or more agronomic characteristics of the plant in association with a Cas endonuclease that creates a double strand break at the polynucleotide and generating the pl... | Compositions and methods are provided for agronomic trait modification of a target sequence in the genome of a plant or plant cell. The methods and compositions employ a guide RNA/Cas endonuclease system to provide an effective system for modifying or altering target sites within a genomic region of a plant, plant cell... | 1,600 |
1,169 | 16,073,105 | 1,631 | Systems and methods are presented that allow for selection of tumor neoepitopes that are filtered for various criteria. In particularly contemplated aspects, filtering includes a step in which the mutation leading to the neoepitope is ascertained as being located in a cancer driver gene. | 1-32. (canceled) 33. A method of treating a cancer in a patient using immune therapy, comprising:
obtaining from a patient omics data from a tumor tissue and a matched normal tissue, and using the omics data to determine a plurality of expressed missense based patient- and tumor-specific neoepitopes; deriving from the ... | Systems and methods are presented that allow for selection of tumor neoepitopes that are filtered for various criteria. In particularly contemplated aspects, filtering includes a step in which the mutation leading to the neoepitope is ascertained as being located in a cancer driver gene.1-32. (canceled) 33. A method of... | 1,600 |
1,170 | 15,997,481 | 1,644 | Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the ant... | 1. An isolated human monoclonal antibody that specifically binds to human tissue factor pathway inhibitor (TFPI), comprising:
(a) a heavy chain variable region, comprising:
a CDR1 region comprising F27, T28, F29, Y32, and M34;
a CDR2 region comprising 151, S54, T58, Y59, Y60, A61, D62, S63, V64, K65, and G66; and
a CDR... | Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the ant... | 1,600 |
1,171 | 13,634,093 | 1,617 | Improved aqueous herbicidal compositions comprising at least one water-soluble herbicide and a gel forming agent are provided. The compositions are generally characterized as pseudoplastic, elastic and having a relatively high stationary viscosity. The compositions provide enhanced foliar retention and resistance to dr... | 1. An aqueous agrochemical gel composition comprising:
(1) from 0.1 to 5 percent by weight on an acid equivalent basis of a water-soluble agrochemical component comprising at least one water-soluble agrochemical, (2) from 0.1 to 5 percent by weight of a polymeric gel forming agent component comprising at least one poly... | Improved aqueous herbicidal compositions comprising at least one water-soluble herbicide and a gel forming agent are provided. The compositions are generally characterized as pseudoplastic, elastic and having a relatively high stationary viscosity. The compositions provide enhanced foliar retention and resistance to dr... | 1,600 |
1,172 | 15,751,542 | 1,627 | This disclosure provides a dosage regimen for co-administration of enzalutamide and a strong CYP3A4 inducer in the treatment of cancer. | 1. A method of treating cancer, comprising co-administration to a patient in need thereof a therapeutically effective dose of enzalutamide and a CYP3A4 inducer, wherein the therapeutically effective dose of enzalutamide is 200-300 mg per day. 2. The method of claim 1, wherein the cancer is selected from the group consi... | This disclosure provides a dosage regimen for co-administration of enzalutamide and a strong CYP3A4 inducer in the treatment of cancer.1. A method of treating cancer, comprising co-administration to a patient in need thereof a therapeutically effective dose of enzalutamide and a CYP3A4 inducer, wherein the therapeutica... | 1,600 |
1,173 | 15,337,302 | 1,623 | A method is provided for the post-treatment of nanoporous celluloses with an eye to scale up to plant operation wherein recycling and recovery of reagents is crucial in the efficient and cost effective operation of a full-scale plant. The instant method includes diminishing the alkali (e.g., sodium hydroxide) concentra... | 1. A method of treating and stabilizing a cellulosic material, comprising
a) contacting a cellulosic material with a treatment solution of an alkali in an alcohol/water co-solvent to yield a treated cellulosic material and dissolved phytochemicals in a post-treatment solution, b) treating the post-treatment solution wi... | A method is provided for the post-treatment of nanoporous celluloses with an eye to scale up to plant operation wherein recycling and recovery of reagents is crucial in the efficient and cost effective operation of a full-scale plant. The instant method includes diminishing the alkali (e.g., sodium hydroxide) concentra... | 1,600 |
1,174 | 13,483,190 | 1,619 | The present invention aims to provide a particulate formulation with an effectively controlled dissolution characteristic of a drug even if the average particle diameter is small. The present invention provides a particulate formulation containing drug particles and a first coating layer coating the drug particles and ... | 1. A particulate formulation containing drug particles and a first coating layer coating said drug particles, characterized in that said first coating layer contains a water-insoluble polymer, inorganic particles, and/or a lipid component and said lipid component contains a C15 or higher fatty acid. 2. The particulate ... | The present invention aims to provide a particulate formulation with an effectively controlled dissolution characteristic of a drug even if the average particle diameter is small. The present invention provides a particulate formulation containing drug particles and a first coating layer coating the drug particles and ... | 1,600 |
1,175 | 15,660,924 | 1,612 | Compositions, devices, and methods for transdermal administration of active agents provided in their salt form instead of neutral form are provided. | 1. A composition for transdermal delivery, comprising:
a drug reservoir comprising an amine salt form of an active agent and an amphoteric inorganic base compound, wherein the pKa of the amphoteric inorganic base compound is lower than that of the amine salt form of the active agent. 2. The composition of claim 1, wher... | Compositions, devices, and methods for transdermal administration of active agents provided in their salt form instead of neutral form are provided.1. A composition for transdermal delivery, comprising:
a drug reservoir comprising an amine salt form of an active agent and an amphoteric inorganic base compound, wherein ... | 1,600 |
1,176 | 15,763,892 | 1,645 | The present invention provides compositions or vaccines that contain a recombinant or an attenuated Leptospira interrogans that elicit an immune response in animals against Leptospira infection, including compositions comprising said recombinant or attenuated L. interrogans, methods of vaccination against Leptospira, a... | 1. A composition or vaccine comprising a recombinant or an attenuated Leptospira interrogans, wherein the Leptospira interrogans comprises a mutated non-functional fliM gene. 2. The composition or vaccine of claim 1, wherein the mutated fliM gene encodes a mutated fliM protein, and wherein the C-terminal region of the ... | The present invention provides compositions or vaccines that contain a recombinant or an attenuated Leptospira interrogans that elicit an immune response in animals against Leptospira infection, including compositions comprising said recombinant or attenuated L. interrogans, methods of vaccination against Leptospira, a... | 1,600 |
1,177 | 15,521,490 | 1,616 | An oil-in-water emulsified sunblock cosmetic has excellent feeling when used and maintains a high ultraviolet-ray protective effect even upon contact with water or sweat. The oil-in-water emulsified sunblock cosmetic contains an (A) ultraviolet-ray protective agent and a (B) fatty acid forming a solid at room temperatu... | 1. An oil-in-water emulsion sunscreen cosmetic, comprising:
(A) a UV protective agent; (B) a fatty acid that is solid at room temperature; wherein a neutralization rate of the fatty acid is 51% or less; and wherein a blending ratio ((A)/(B)) between the (A) UV protective agent and the (B) fatty acid that is solid at ro... | An oil-in-water emulsified sunblock cosmetic has excellent feeling when used and maintains a high ultraviolet-ray protective effect even upon contact with water or sweat. The oil-in-water emulsified sunblock cosmetic contains an (A) ultraviolet-ray protective agent and a (B) fatty acid forming a solid at room temperatu... | 1,600 |
1,178 | 14,441,352 | 1,619 | The present invention relates to a cosmetic composition comprising
one or more dicarbonyl compound corresponding to formula (I) below thereof and/or hydrates thereof and/or salts thereof:
in which formula (I) R═H... | 1. Cosmetic composition comprising
one or more dicarbonyl compounds corresponding to formula (I) below and/or hydrates thereof and/or salts thereof:
in which formula (I):
R represents an atom or group chosen from i) hydrogen, ii) carboxyl —C(O)OH, iii) linear or branched C1-C6 alkyl which is optionally subs... | The present invention relates to a cosmetic composition comprising
one or more dicarbonyl compound corresponding to formula (I) below thereof and/or hydrates thereof and/or salts thereof:
in which formula (I) R═H... | 1,600 |
1,179 | 16,261,459 | 1,627 | Disclosed herein are methods of administering pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist to a subject in need of treatment of emesis. | 1. A method for treating a subject in need thereof, comprising intravenously administering to the subject a single dose of a stable emulsion at an average rate of about 6.5 to 70 mg/minute of an NK-1 receptor antagonist comprised in the stable emulsion, wherein the stable emulsion comprises:
the NK-1 receptor antagonis... | Disclosed herein are methods of administering pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist to a subject in need of treatment of emesis.1. A method for treating a subject in need thereof, comprising intravenously administering to the subject a single dose of a stable emulsion at an average ra... | 1,600 |
1,180 | 11,503,418 | 1,618 | In one embodiment, a composition comprises a microparticle including a radioactive isotope and an imageable element. In another embodiment, a method includes forming a microparticle including a target isotope and an enriched paramagnetic isotope, and transforming the target isotope into a radioactive isotope. In yet an... | 1. A composition comprising
a microparticle including a radioactive isotope and an imageable element. 2. The composition of claim 1, wherein the imageable element comprises a paramagnetic material. 3. The composition of claim 1, wherein the imageable element comprises an enriched paramagnetic isotope. 4. The compositio... | In one embodiment, a composition comprises a microparticle including a radioactive isotope and an imageable element. In another embodiment, a method includes forming a microparticle including a target isotope and an enriched paramagnetic isotope, and transforming the target isotope into a radioactive isotope. In yet an... | 1,600 |
1,181 | 14,636,729 | 1,619 | The invention relates to cleaning and food processing aide applications whereby unique compositions of GRAS or food additives were developed to assess the effectiveness of cleaning procedures at various stages of the processes and to assess the delivery and adherence of food processing aides. Employing such solutions t... | 1-3. (canceled) 4. A method of processing a food, an animal hide or a hard surface comprising the steps of:
applying a composition to a surface of the food, the animal hide or the hard surface; and visually inspecting the surface of the food, the animal hide or the hard surface under ultraviolet light to detect fluores... | The invention relates to cleaning and food processing aide applications whereby unique compositions of GRAS or food additives were developed to assess the effectiveness of cleaning procedures at various stages of the processes and to assess the delivery and adherence of food processing aides. Employing such solutions t... | 1,600 |
1,182 | 12,253,943 | 1,653 | A unique, innovative, and efficient system in order to convert ferulic acid into vanillin which involves the immobilization of actinomycetes in an effective solid support structure which is comprised of one or more pieces of a material, that is configured so as to allow effective aeration.
For the immobilization ... | 1. A biotransformation process to produce vanillin from cinnamic acid derivatives which is comprised of the following steps:
(a) immobilizing a microorganism from the actinomycetales group in an effective solid support structure, said solid support structure comprising one or more pieces of a material which is effectiv... | A unique, innovative, and efficient system in order to convert ferulic acid into vanillin which involves the immobilization of actinomycetes in an effective solid support structure which is comprised of one or more pieces of a material, that is configured so as to allow effective aeration.
For the immobilization ... | 1,600 |
1,183 | 16,291,297 | 1,613 | The present invention provides a composition comprising a high load of metal oxides that is phase stable and sprayable. It comprises a branched hydrophobically modified ethoxylated urethane copolymer and a hydrophobically modified alkali swellable emulsion copolymer comprising of one or more acrylate monomers and an et... | 1.-10. (canceled) 11. A composition comprising at least about 10 weight percent of a metal oxide having a viscosity less than 50,000 cP within a shear rate rage of 0.01 to 0.1 s−1, and a loss tangent greater than 2.5 in an angular frequency range of 0.1 to 1 rad/s. 12. The composition of claim 11, wherein the metal oxi... | The present invention provides a composition comprising a high load of metal oxides that is phase stable and sprayable. It comprises a branched hydrophobically modified ethoxylated urethane copolymer and a hydrophobically modified alkali swellable emulsion copolymer comprising of one or more acrylate monomers and an et... | 1,600 |
1,184 | 14,932,986 | 1,653 | A selective isolation medium that is not influenced by existence of ESBL-producing bacteria and can clearly detect Campylobacter bacteria.
Cefoperazone and Cefoxitin are incorporated into the culture medium for detecting Campylobacter bacteria. | 1. A method for detecting Campylobacter bacteria, comprising:
a step of inoculating a specimen to a culture medium comprising Cefoperazone and Cefoxitin; a step of culturing Campylobacter bacteria contained in the specimen; and a step of detecting colony of Campylobacter bacteria. 2. The method according to claim 1, wh... | A selective isolation medium that is not influenced by existence of ESBL-producing bacteria and can clearly detect Campylobacter bacteria.
Cefoperazone and Cefoxitin are incorporated into the culture medium for detecting Campylobacter bacteria.1. A method for detecting Campylobacter bacteria, comprising:
a st... | 1,600 |
1,185 | 15,378,165 | 1,645 | The present invention relates to compositions or vaccines for combating Mycoplasma hyopneumoniae (M hyo), Porcine Circovirus type 2 (PCV2), and Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) infections in animals and for increasing the ability of pigs to gain weight and/or improve death loss, methods of ... | 1. A composition or vaccine comprising: i) an M hyo antigen, and ii) a porcine circovirus type 2 (PCV2) antigen, a Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) antigen, or a combination thereof. 2. The composition or vaccine of claim 1, wherein the composition of vaccine comprises an M hyo antigen and a ... | The present invention relates to compositions or vaccines for combating Mycoplasma hyopneumoniae (M hyo), Porcine Circovirus type 2 (PCV2), and Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) infections in animals and for increasing the ability of pigs to gain weight and/or improve death loss, methods of ... | 1,600 |
1,186 | 16,050,059 | 1,612 | Described herein are oral care compositions comprising a zinc ion source, a fluoride ion source, and a basic amino acid; along with methods of making and using the same. | 1-12. (canceled) 13. A method of treating or reducing dental enamel erosion comprising administering a composition to the oral cavity of a subject in need thereof, wherein the composition comprises, based on the weight of the composition:
from 0.5 to 2.5% by weight of a zinc ion source comprising zinc citrate; about 14... | Described herein are oral care compositions comprising a zinc ion source, a fluoride ion source, and a basic amino acid; along with methods of making and using the same.1-12. (canceled) 13. A method of treating or reducing dental enamel erosion comprising administering a composition to the oral cavity of a subject in n... | 1,600 |
1,187 | 15,305,410 | 1,699 | A NOx concentration measurement system has a NOx sensor, a detection section, a NH 3 concentration estimation section and a calculation section. The NOx sensor measures a sum concentration c 4 of a concentration of NOx (a concentration c 1 of combustion derived NOx) in exhaust gas g, and a concentration of NO (conce... | 1. A NOx concentration measurement system capable of measuring a concentration of NOx contained in exhaust gas which contains NOx and NH3, comprising a NOx sensor, a detection section, a NH3 concentration estimation section, and a calculation section, wherein
the NOx sensor comprises: a gas chamber into which exhaust g... | A NOx concentration measurement system has a NOx sensor, a detection section, a NH 3 concentration estimation section and a calculation section. The NOx sensor measures a sum concentration c 4 of a concentration of NOx (a concentration c 1 of combustion derived NOx) in exhaust gas g, and a concentration of NO (conce... | 1,600 |
1,188 | 13,518,971 | 1,612 | The present invention relates to oral care compositions with improved flavor release characteristics and improved taste, and methods of using the same. | 1. An oral care composition comprising:
a whitening agent, wherein the whitening agent is bound; an anionic surfactant present in an amount from 1.75% to 2.0% w/w; and an orally acceptable carrier having a total concentration of water of 0% to 4% w/w and wherein the water content of the oral care composition is less th... | The present invention relates to oral care compositions with improved flavor release characteristics and improved taste, and methods of using the same.1. An oral care composition comprising:
a whitening agent, wherein the whitening agent is bound; an anionic surfactant present in an amount from 1.75% to 2.0% w/w; and a... | 1,600 |
1,189 | 15,577,969 | 1,634 | The present invention relates to methods for diagnosing, monitoring or prognosticating prostate cancer or the progression state of prostate cancer wherein said method determines the state of the prostate cancer, based on the expression level of phosphodiesterase 4D (PDE4D) variants. The invention further relates to a m... | 1. A method comprising the step of:
a) determining a prostate cancer progression state based on a gene expression profile including the expression level of at least two phosphodiesterase 4D (PDE4D) variants selected from the group consisting of PDE4D1, PDE4D2, PDE4D3, PDE4D4, PDE4D5, PDE4D6, PDE4D7, PDE4D8 and PDE4D9, ... | The present invention relates to methods for diagnosing, monitoring or prognosticating prostate cancer or the progression state of prostate cancer wherein said method determines the state of the prostate cancer, based on the expression level of phosphodiesterase 4D (PDE4D) variants. The invention further relates to a m... | 1,600 |
1,190 | 15,027,429 | 1,653 | It has been found in accordance with the invention that a biomass comprising an oxidation-sensitive material of value may be particularly readily converted into a particulate, flowable composition if a silica, especially a hydrophilic or hydrophobic silica, is added as additive. | 1-15. (canceled) 16. A method for preparing a particulate free-flowing biomass comprising an oxidation-sensitive material of value, wherein said method comprises:
a) obtaining a fermentation broth comprising biomass; b) optionally concentrating said fermentation broth to produce a concentrated broth; c) drying either s... | It has been found in accordance with the invention that a biomass comprising an oxidation-sensitive material of value may be particularly readily converted into a particulate, flowable composition if a silica, especially a hydrophilic or hydrophobic silica, is added as additive.1-15. (canceled) 16. A method for prepari... | 1,600 |
1,191 | 13,412,887 | 1,631 | Methods and articles of manufacture for modeling molecular properties using data regarding the partial orderings of compound properties, or by considering measurements of compound properties in terms of partial orderings are disclosed. One embodiment provides for constructing such partial orderings from data that is no... | 1-10. (canceled) 11. A method for training a molecular properties model, comprising:
obtaining a pseudo-partial ordering of molecules, wherein the pseudo partial ordering includes at least a representation of a first and second molecule, ordered relative to one another and a property of interest; and generating a repre... | Methods and articles of manufacture for modeling molecular properties using data regarding the partial orderings of compound properties, or by considering measurements of compound properties in terms of partial orderings are disclosed. One embodiment provides for constructing such partial orderings from data that is no... | 1,600 |
1,192 | 16,285,457 | 1,649 | Methods and compositions are disclosed for enhancing neurogenesis, resolving neuropathy and improving neurological health and functioning using fungal extracts and their active ingredients, including species of mushrooms and mycelia containing psilocybin and psilocin, combined with erinacines and hericenones or fungal ... | 1. A composition comprising:
0.1 mg to 10 mg of psilocybin, psilocin, baeocystin, norbaeocystin, salts thereof, or combinations thereof, or about 0.1 gram to 1 gram of psilocybin mushrooms, or combinations thereof; 0.1 mg to 200 mg of erinacines, hericenones or combinations thereof; and 1 mg to 200 mg of niacin. 2. The... | Methods and compositions are disclosed for enhancing neurogenesis, resolving neuropathy and improving neurological health and functioning using fungal extracts and their active ingredients, including species of mushrooms and mycelia containing psilocybin and psilocin, combined with erinacines and hericenones or fungal ... | 1,600 |
1,193 | 15,312,409 | 1,663 | The disclosure relates to improving plant breeding methods by controlling for microbial diversity present in the plant breeding process. | 1. A method for controlling the microbial variability associated with selective plant breeding, comprising:
a) subjecting one or more plants to a growth medium in the presence of a first set of one or more microorganisms; b) selecting one or more plants and/or growth medium following step a); c) acquiring a second set ... | The disclosure relates to improving plant breeding methods by controlling for microbial diversity present in the plant breeding process.1. A method for controlling the microbial variability associated with selective plant breeding, comprising:
a) subjecting one or more plants to a growth medium in the presence of a fir... | 1,600 |
1,194 | 15,751,889 | 1,619 | Use of a water-soluble polymer having a solubility in water of greater than 5% (m/m) in the pH range of 1 to 13 and which is obtained by free-radically initiated polymerization of a monomer mixture of i) 70 to 90% by weight N-vinylpyrrolidone and ii) 10 to 30% by weight acrylic acid, wherein the sum total of i) and ii)... | 1. A method of formulating a basic active ingredient sparingly soluble in water comprising adding a water-soluble polymer having a solubility in water of greater than 5% (m/m) in a pH range of 1 to 13 and which is obtained by a free-radically initiated polymerization of a monomer mixture of i) 70 to 90% by weight N-vin... | Use of a water-soluble polymer having a solubility in water of greater than 5% (m/m) in the pH range of 1 to 13 and which is obtained by free-radically initiated polymerization of a monomer mixture of i) 70 to 90% by weight N-vinylpyrrolidone and ii) 10 to 30% by weight acrylic acid, wherein the sum total of i) and ii)... | 1,600 |
1,195 | 16,157,263 | 1,613 | A wipe includes a cleansing composition disposed on a cloth. The cleansing composition can include an antiseptic, a humectant, an emollient, a surfactant, and a monohydric alcohol. A wipe can be made by preparing a cleansing composition and disposing the cleansing composition on a cloth. Two or more wipes may be includ... | 1. A wipe comprising:
a nonwoven cloth comprising plural fibers having a denier in the range from 2.6 to 3.7, and a cleansing composition disposed on the cloth, the cleansing composition comprising chlorhexidine gluconate in an amount sufficient to reduce the number of active pathogens present on skin upon contact betw... | A wipe includes a cleansing composition disposed on a cloth. The cleansing composition can include an antiseptic, a humectant, an emollient, a surfactant, and a monohydric alcohol. A wipe can be made by preparing a cleansing composition and disposing the cleansing composition on a cloth. Two or more wipes may be includ... | 1,600 |
1,196 | 16,115,973 | 1,612 | A process for treating tumors by administering a mixture of cancer fighting drugs incorporated into a stabilized liposomal formulation. Each cancer drug is selected to target a different phase of the cell-cycle of the cancer cell thus expanding the number of cancer cells that can be killed at one time without compromis... | 1-13. (canceled) 14. A method for forming a pharmaceutical composition for targeting tumor cells based upon their proliferative capacity, the method comprising the steps of:
selecting a first cytotoxic drug based upon that first cytotoxic drug selectively targeting a first phase in the cell-cycle of tumor cells; select... | A process for treating tumors by administering a mixture of cancer fighting drugs incorporated into a stabilized liposomal formulation. Each cancer drug is selected to target a different phase of the cell-cycle of the cancer cell thus expanding the number of cancer cells that can be killed at one time without compromis... | 1,600 |
1,197 | 15,304,626 | 1,616 | Vitamin E-based amphiphilic copolymers are disclosed. Compositions containing vitamin E-based amphiphilic copolymers and/or nanocarriers are also disclosed. Methods of making vitamin E-based amphiphilic copolymers and/or nanocarriers and methods of using vitamin E-based amphiphilic copolymers and/or nanocarriers are al... | 1. An amphiphilic copolymer comprising:
polyethylene glycol, and three or more vitamin E units bonded to the polyethylene glycol. 2. A crosslinked amphiphilic copolymer comprising:
polyethylene glycol, and two or more vitamin E units bonded to the polyethylene glycol. 3. The amphiphilic copolymer of claim 2, wherein sa... | Vitamin E-based amphiphilic copolymers are disclosed. Compositions containing vitamin E-based amphiphilic copolymers and/or nanocarriers are also disclosed. Methods of making vitamin E-based amphiphilic copolymers and/or nanocarriers and methods of using vitamin E-based amphiphilic copolymers and/or nanocarriers are al... | 1,600 |
1,198 | 16,456,177 | 1,642 | The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorecta... | 1-15. (canceled) 16. A method of treating bladder cancer in a human patient, comprising administering to the patient a therapeutically effective amount of a compound of formula (I)
wherein
anti-HER2 Ab is an anti-HER2 antibody or antibody fragment able to bind HER2,
n is 0, 1, 2, or 3,
m represents an average... | The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorecta... | 1,600 |
1,199 | 16,090,692 | 1,612 | The invention provides liquid cleansing composition comprising having mild surfactant, specifically salts of N-acyl polycarboxylic acid where pH of composition is preferably 6.5 and below. By combining with particular defibrillated cell wall materials, the mild surfactants can be structured and also have surprisingly g... | 1. A cleansing composition comprising:
1) 0.5 to 35% by wt. of total composition of a surfactant system which contains:
a) 0.5 to 25% by wt. of total composition anionic surfactant and
b) 0 to 20% by wt. of a co-surfactant selected from the group consisting of non-ionic surfactant, cationic surfactant, amphoteric surfa... | The invention provides liquid cleansing composition comprising having mild surfactant, specifically salts of N-acyl polycarboxylic acid where pH of composition is preferably 6.5 and below. By combining with particular defibrillated cell wall materials, the mild surfactants can be structured and also have surprisingly g... | 1,600 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.